CMVLF (Cellectis) 5-Year Yield-on-Cost %: 0.00 (As of Jul. 12, 2026)


CMVLF Cellectis SA CMVLF
59 GF Score
Price $3.47
GF Value $3.28
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Cellectis 5-Year Yield-on-Cost %?

Cellectis CMVLF 59 5-Year Yield-on-Cost % is 0.00 as of Jul. 12, 2026. GuruFocus rates CMVLF with a GF Score™ of 59/100 and a GF Value™ of $3.28 (Fairly Valued). The stock has 4 warning signs investors should review. Among 153 Biotechnology companies, Cellectis ranks worse than 653594.12% on this metric.

Cellectis's yield on cost for the quarter that ended in Mar. 2026 was 0.00.


The historical rank and industry rank for Cellectis's 5-Year Yield-on-Cost % or its related term are showing as below:



CMVLF's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.7
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Cellectis  (OTCPK:CMVLF) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Cellectis 5-Year Yield-on-Cost % Related Terms


CMVLF vs VRTX, REGN, ALNY: 5-Year Yield-on-Cost % Comparison

For the Biotechnology subindustry, Cellectis's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cellectis 5-Year Yield-on-Cost % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cellectis's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Cellectis's 5-Year Yield-on-Cost % falls into.


CMVLF
59GF Score
Cellectis SA CMVLF
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cellectis 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Cellectis is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Cellectis (CMVLF) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 12, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Cellectis and its competitors. According to the industry distribution chart, Cellectis ranks #999999 out of 153 companies in the Biotechnology industry.
Is Cellectis' 5-Year Yield-on-Cost % too high?
Cellectis' current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Cellectis ranks #999999 out of 153 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cellectis has a GF Score™ of 59/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cellectis' 5-Year Yield-on-Cost % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cellectis ranks #999999 out of 153 companies for 5-Year Yield-on-Cost %. This places Cellectis in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.70, based on 153 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Cellectis and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cellectis's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cellectis stock overvalued right now?
Based on GuruFocus' analysis, Cellectis (CMVLF) is currently considered Fairly Valued. The stock's GF Value™ is $3.28, compared to a current price of $3.47 — trading 5.8% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Cellectis' overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Cellectis (CMVLF), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cellectis (CMVLF) Overvalued in 2026?

Based on GuruFocus' analysis, Cellectis stock appears to be overvalued. The current stock price of $3.47 is trading 5.8% above its estimated GF Value™ of $3.28. GuruFocus considers Cellectis to be Fairly Valued.

Key valuation signals for CMVLF:

  • 5-Year Yield-on-Cost %: 0.00
  • GF Value™: $3.28 vs. price of $3.47 (5.8% above fair value)
  • GF Score™: 59/100 with 4 warning signs

No single metric tells the full story. See the CMVLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cellectis Business Description

Address 8, rue de la Croix Jarry, Paris, FRA, 75013
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
59GF Score

Get the complete analysis for CMVLF

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.47
Price
$3.28
GF Value